Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors. Dumbrava EE, Shapiro GI, Parikh AR, Johnson ML, et al. N Engl J Med 2026;394:872-883.

Read + Share

Amedeo Smart

Independent Medical Education

Dumbrava EE, Shapiro GI, Parikh AR, Johnson ML, et al. Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors. N Engl J Med 2026;394:872-883.
PMID: 41740031